A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009267/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this multi-center study is to evaluate the efficacy and safety of daprodustat
in subjects with anemia associated with CKD.
提供机构：
Vivli
创建时间：
2023-09-12
